LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

Search

Moderna Inc

Geschlossen

Branche Gesundheitswesen

54.49 -0.04

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

54.29

Max

55.13

Schlüsselkennzahlen

By Trading Economics

Einkommen

-104M

-1.3B

Verkäufe

-167B

241M

KGV

Branchendurchschnitt

35.86

106.547

EPS

-3.33

Gewinnspanne

-530.705

Angestellte

5,600

EBITDA

-109M

-1.2B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+71.57 upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Nov. 2024

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

522M

21B

Vorheriger Eröffnungskurs

54.53

Vorheriger Schlusskurs

54.49

Nachrichtenstimmung

By Acuity

100%

0%

371 / 389 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Moderna Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Dez. 2023, 13:16 UTC

Wichtige Markttreiber

Moderna Shares, Other Covid Vaccine Makers Hit by Warning From Pfizer

28. Okt. 2024, 13:48 UTC

Ergebnisse

Moderna's Stock-Price Target Slashed. It's About Vaccines. -- Barrons.com

15. Sept. 2024, 07:00 UTC

Top News

World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna -- Barrons.com

12. Sept. 2024, 15:02 UTC

Top News

Moderna Cost Cuts Fail to Restore Investor Trust -- Heard on the Street -- WSJ

12. Sept. 2024, 10:00 UTC

Top News

Moderna Pulls Back on R&D and Delays Timeline for Profitability -- Barrons.com

6. Sept. 2024, 11:00 UTC

Top News

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

3. Sept. 2024, 04:00 UTC

Top News

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

23. Aug. 2024, 18:38 UTC

Top News

The U.S. Is Bringing Back Free Covid Tests This Fall -- Barrons.com

2. Aug. 2024, 21:29 UTC

Top News

The Score: CrowdStrike, Apple, Intel and More Stocks That Defined the Week -- WSJ

1. Aug. 2024, 10:30 UTC

Top News

Moderna Cuts Revenue Guidance Amid Steeper Competition -- Barrons.com

3. Juli 2024, 14:18 UTC

Akquisitionen, Fusionen, Übernahmen

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

30. Mai 2024, 19:45 UTC

Top News

Bird Flu Confirmed in Third Farmworker. It's the First Case With Respiratory Symptoms. -- Barrons.com

29. Mai 2024, 15:56 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

10. Mai 2024, 20:11 UTC

Ergebnisse

These Stocks Moved the Most Today: Novavax, Akamai, Sweetgreen, Taiwan Semi, Moderna, Gen Digital, JFrog, SoundHound, and More -- Barrons.com

10. Mai 2024, 14:49 UTC

Ergebnisse
Heiße Aktien

Stocks to Watch Friday: TSMC, Novavax, Nvidia -- WSJ

2. Mai 2024, 13:46 UTC

Ergebnisse
Heiße Aktien

Stocks to Watch Thursday: Carvana, NIO, Qualcomm, Peloton -- WSJ

2. Mai 2024, 10:31 UTC

Ergebnisse

Moderna Puts Up Big Quarterly Beat; Could Shares Notch A Breakout? -- IBD

2. Mai 2024, 09:08 UTC

Heiße Aktien

Stocks to Watch Thursday: Shell, Novo Nordisk, Apple -- WSJ

28. Feb. 2024, 14:14 UTC

Ergebnisse

Novavax Stock Sinks as Revenue Misses Estimates in 'Transition Year' -- Barrons.com

22. Feb. 2024, 16:00 UTC

Top News

Moderna Is Pivoting From Covid and the Results Are on Their Way -- Heard on the Street -- WSJ

22. Feb. 2024, 12:40 UTC

Ergebnisse

Moderna Stock Jumps on Surprise Profit After Earnings Beat. What to Expect in 2024. -- Barrons.com

Peer-Vergleich

Kursveränderung

Moderna Inc Prognose

Kursziel

By TipRanks

71.57% Vorteil

12-Monats-Prognose

Durchschnitt 93.73 USD  71.57%

Hoch 238 USD

Tief 46 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Moderna Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

19 ratings

7

Buy

10

Halten

2

Sell

Technischer Score

By Trading Central

53.05 / 54.76Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

371 / 389 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Moderna Inc

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.